Search

everythinglearnresearchcommunity

for

Search:↓

Guselkumab effectively reduces fatigue in Psoriatic Arthritis patients over two years.

Biosimilars lower costs but don't significantly improve access.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Ixekizumab has known and some unexpected side effects.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Fremanezumab effectively reduces migraines and improves quality of life with mild side effects.

A medication for skin rash also unexpectedly treated hair loss in a patient.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Adalimumab can cause complete hair loss in rare cases.

Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.

These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

Teriflunomide is an effective and generally safe oral treatment for relapsing MS, reducing relapses and slowing disability progression.

Dupilumab effectively treated severe alopecia areata in a child.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Secukinumab treatment may cause HBV reactivation and hair discoloration.

A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

A patient's grey hair regained color during treatment with adalimumab.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

Mogamulizumab treatment in Sézary syndrome may cause skin issues and hair loss but can lead to a complete response.